Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Primate cell – per se
Reexamination Certificate
2010-02-17
2011-12-27
Belyavskyi, Michail (Department: 1644)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Primate cell, per se
Reexamination Certificate
active
08084255
ABSTRACT:
A method of in vitro fucosylation of selectin ligands on cord blood-derived hematopoietic stem cells for bone marrow transplantation is disclosed. In this method, an effective amount of an α1,3-fucosyltransferase, e.g., α1,3-fucosyltransferase VI, is used in vitro to treat cord blood-derived hematopoietic stem cells to convert non-functional PSGL-1 or other ligands on the cell surface into functional forms that bind selectins, especially P-selectin or E-selectin. The treated cells have enhanced effectiveness in reconstituting bone marrow in patients in need of such therapy.
REFERENCES:
patent: 5004681 (1991-04-01), Boyse et al.
patent: 5192553 (1993-03-01), Boyse et al.
patent: 5858752 (1999-01-01), Seed et al.
patent: 6399337 (2002-06-01), Taylor et al.
patent: 6440110 (2002-08-01), Kuypers et al.
patent: 6461835 (2002-10-01), Cummings et al.
patent: 6485722 (2002-11-01), McIvor et al.
patent: 7776591 (2010-08-01), Xia et al.
patent: 2003/0040607 (2003-02-01), Sackstein et al.
patent: 04716880 (2007-09-01), None
patent: WO 96/40881 (1996-12-01), None
patent: WO 00/06704 (2000-02-01), None
patent: WO 2005/017115 (2005-02-01), None
PCT/US04/06474, Search Report, Dec. 5, 2006.
Frenette et al., “Endothelial selectins and vascular cell adhesion molecule-1 promote hematopoietic progenitor homing to bone marrow”,Proc. Natl. Acad. Sci., USA,Nov. 1998, vol. 95, pp. 14423-14428, Medical Sciences.
Harris et al., “Collection, separation and cryopreservation of umbilical cord blood for use in transplantation”,Bone Marrow Transplantation,1994, vol. 13, pp. 135-143.
Hidalgo et al., “Functional selectin ligands mediating human CD34—+ cell interactions with bone marrow endothelium are enhanced postnatally”,The Journal of Clinical Investigation,Aug. 2002, vol. 110, No. 4, pp. 559-569.
Kobzdej et al., “Discordant expression of selectin ligands and sialyl Lewis x-related epitopes on murine myeloid cells”,Blood,Dec. 15, 2002, vol. 100, No. 13, pp. 4485-4494.
Mazo et al., “Hematopoietic Progenitor Cell Rolling in Bone Marrow Microvessels: Parallel Contributions by Endothelial Selectins and Vascular Cell Adhesion Molecule 1”,J. Exp. Med.,Aug. 3, 1998, vol. 188, No. 3, pp. 465-474.
McEver et al., “Perspectives Series: Cell Adhesion in Vascular Biology”,J. Clin. Invest.,Aug. 1997, vol. 100, No. 3, pp. 485-492.
Nishihira et al., “The Japanese cord blood bank network experience with cord blood transplantation from unrelated donors for haematological malignancies: an evaluation of graft-versus-host disease prophylaxis”,British Journal of Haematology,2003, vol. 120, pp. 516-522.
Ramachandran et al., “Dimerization of a selectin and its ligand stabilizes cell rolling and enhances tether strength in shear flow”,Proc. Natl. Acad. Sci.,Aug. 28, 2001, vol. 98, No. 18, pp. 10166-10171.
Rocha et al., “Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia”,Blood,May 15, 2001, vol. 97, No. 10, pp. 2962-2971.
Stevens et al., “Placental/umbilical cord blood for unrelated-donor bone marrow reconstitution: relevance of nucleated red blood cells”,Blood,Oct. 1, 2002, vol. 100, No. 7, pp. 2662-2664.
Terstappen et al., “Sequential Generations of Hematopoietic Colonies Derived From Single Nonlineage-Committed CD34+CD−Progenitor Cells”,Blood,Mar. 15, 1991, vol. 77, No. 6, pp. 1218-1227.
Thomas, “History, Current Results, and Research in Marrow Transplantation”,Perspectives in Biology and Medicine,Winter 1995, vol. 38, No. 2, pp. 230-237.
Wagers et al., “Interleukin 12 and Interleukin 4 Control T Cell Adhesion to Endothelial Selectins through Opposite Effects on α1,3-fucosyltransferase VII Gene Expression”,J. Exp. Med.,Dec. 21, 1998, vol. 188, No. 12, pp. 2225-2231.
Hidalgo et al.,“Enforced fucosylation of neonatal CD34+cells generages selectin ligands that enhance the initial interactions with microvessels but not homing to bone marrow”Blood,2005, vol. 105, No. 2, pp. 567-575.
Katayama et al. “PSGL-1 pariticipates in E-selectin-mediated progenitor homing to bone marrow: evidence for cooperation between E-selectin ligands anda4 integrin” Blood, 2003, vol. 102, No. 6, pp. 2060-2067.
Greenbert et al., “Relationship between selectin-mediated rolling of hematopoietic stem and progenitor cells and progression in hematopoietic development”, Blood, pp. 478-486, vol. 95, No. 2, Jan. 15, 2000, XP002450253.
Li et al., “Post-translational Modifications of Recombinant P-selectin Glycoprotein Ligand-1 Required for Binding to P- and E-selectin”,Journal of Biological Chemistry,pp. 3255-3264, vol. 271, No. 6, Issue of Feb. 6, 1996, XP002116305.
Snapp et al., “P-Selectin Glycoprotein Ligand-1 Is Essential for Adhesion to P-Selectin But Not E-Selectin in Stably Transfected Hematopoietic Cell Lines”,Blood,vol. 89, No. 3 (Feb. 1, 1997), pp. 896-901.
Da Silva et al., “Differences Amid Bone Marrow and Cord Blood Hematopoietic Stem/Progenitor Cell Division Kinetics”,Journal of Cellular Physiology,published online Mar. 10, 2009, Wiley InterScience (www.interscience.wiley.com), PP. 102-111.
Grewel et al., “Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood?”Blood,Jun. 1, 2003, vol. 101, No. 11, pp. 4233-4244.
Hao et al., “A functional comparison of CD34 + CD38 cells in cord blood and bone marrow”Blood,Nov. 15, 1995, vol. 86, No. 10, pp. 3745-3753.
Rini et al., “Glycosyltransferases and Glycan-processing Enzymes”Essentials of Glycobiology,Second Edition, published by Cold Spring Harbor Laboratory Press, cold Spring Harbor, New York, 2009 by The Consortium of Glycobiology Editors, La Jolla, California, pp. 63-73.
Theunissen et al., “A multifactorial analysis of umbilical cord blood, adult bone marrow and mobilized peripheral blood progenitors using the improved ML-IC assay”Experimental Hematology,vol. 33 (2005) pp. 165-172.
Van Den Oudenrigin et al., “Differences in megakaryocyte expansion potential between CD34+stem cells derived from cord blood, peripheral blood, and bone marrow from adults and children”Experimental Hematology,vol. 28 (2000) pp. 1054-1061.
Yasui, et al., “Differences Between Peripheral Blood and Cord Blood in the Kinetics of Lineage-Restricted Hematopoietic Cells: Implications for Delayed Platelet Recovery Following Cord Blood Transplantation”Stem Cellsvol. 21 (2003) pp. 143-151.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Office Action mailed Mar. 28, 2008, 6 pgs.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Response mailed Oct. 7, 2008, 9 pgs.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Office Action mailed Nov. 25, 2008, 4 pgs.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Response mailed Jun. 5, 2009, 4 pgs.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Office Action mailed Aug. 3, 2009, 6 pgs.
Xia et al., European Patent Application No. 04716880.2-2405, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Response mailed Feb. 9, 2010, 7 pgs.
Xia et al., Japanese Patent Application No. 2006-509036, “Hematopoietic Stem Cells Treated by In Vitro Fucosylation and Methods of Use” Office Action mailed Dec. 28. 2009 5 pgs (2 pgs in Japanese; 3 pgs in English Translation).
McEver Rodger P.
Xia Lijun
Belyavskyi Michail
Dunlap Codding P.C.
Oklahoma Medical Research Foundation
LandOfFree
Stem cells treated by in vitro fucosylation and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stem cells treated by in vitro fucosylation and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stem cells treated by in vitro fucosylation and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4308193